{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:34:10Z","timestamp":1792632850814,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T00:00:00Z","timestamp":1403827200000},"content-version":"vor","delay-in-days":511,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.critrevonc.2012.06.004","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T19:57:24Z","timestamp":1342295844000},"page":"206-215","source":"Crossref","is-referenced-by-count":128,"title":["Anaplastic large cell lymphoma, ALK-negative"],"prefix":"10.1016","volume":"85","author":[{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Govi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (7)","key":"10.1016\/j.critrevonc.2012.06.004_bib0005","first-page":"574","article-title":"Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options","volume":"24","author":"Querfeld","year":"2010","journal-title":"Oncology (Williston Park)"},{"issue":"June (12)","key":"10.1016\/j.critrevonc.2012.06.004_bib0010","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.06.004_bib0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1182\/blood.V116.21.322.322","article-title":"Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d\u2019Etude Des Lymphomes De l\u2019Adulte (GELA)","volume":"116","author":"Sibon","year":"2010","journal-title":"Blood"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2012.06.004_bib0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.humpath.2003.10.013","article-title":"Absence of Epstein\u2013Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria","volume":"35","author":"Herling","year":"2004","journal-title":"Human Pathology"},{"issue":"April (8)","key":"10.1016\/j.critrevonc.2012.06.004_bib0025","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Ekstr\u00f6m Smedby","year":"2008","journal-title":"Blood"},{"issue":"October (19 Suppl.)","key":"10.1016\/j.critrevonc.2012.06.004_bib0030","first-page":"5503s","article-title":"Neiman RS.Non-Hodgkin's lymphoma and occupational exposure","volume":"52","author":"Scherr","year":"1992","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.06.004_bib0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ajim.4700180310","article-title":"Environmental epidemiology of non-Hodgkin's lymphoma in eastern Nebraska","volume":"18","author":"Weisenburger","year":"1990","journal-title":"American Journal of Industrial Medicine"},{"issue":"September (5)","key":"10.1016\/j.critrevonc.2012.06.004_bib0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00001648-199009000-00004","article-title":"A case\u2013control study of non-Hodgkin's lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska","volume":"1","author":"Zahm","year":"1990","journal-title":"Epidemiology"},{"issue":"September (3)","key":"10.1016\/j.critrevonc.2012.06.004_bib0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bjc.1989.290","article-title":"Occupation and lymphoid neoplasms","volume":"60","author":"La Vecchia","year":"1989","journal-title":"British Journal of Cancer"},{"issue":"October (7)","key":"10.1016\/j.critrevonc.2012.06.004_bib0050","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/DAD.0b013e3181d46eba","article-title":"Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration","volume":"32","author":"Marschalk\u00f3","year":"2010","journal-title":"American Journal of Dermatopathology"},{"issue":"November (17)","key":"10.1016\/j.critrevonc.2012.06.004_bib0055","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/jama.2008.585","article-title":"Anaplastic large-cell lymphoma in women with breast implants","volume":"300","author":"de Jong","year":"2008","journal-title":"JAMA"},{"issue":"July (4)","key":"10.1016\/j.critrevonc.2012.06.004_bib0060","first-page":"389","article-title":"Oral hypoglycemic use and the SANDS trial","volume":"300","author":"Evans","year":"2008","journal-title":"JAMA"},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2012.06.004_bib0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/modpathol.3801024","article-title":"Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder","volume":"21","author":"Roden","year":"2008","journal-title":"Modern Pathology"},{"key":"10.1016\/j.critrevonc.2012.06.004_bib0070","series-title":"American Society of Plastic Surgeons Annual Conference","article-title":"T cell non-Hodgkin's anaplastic lymphoma associated with one style of breast implants","author":"Brody","year":"2010"},{"issue":"November (10)","key":"10.1016\/j.critrevonc.2012.06.004_bib0075","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2004-03-1037","article-title":"Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling","volume":"104","author":"Bonzheim","year":"2004","journal-title":"Blood"},{"issue":"November (10)","key":"10.1016\/j.critrevonc.2012.06.004_bib0080","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood.V88.10.4005.bloodjournal88104005","article-title":"Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules","volume":"88","author":"Foss","year":"1996","journal-title":"Blood"},{"issue":"March (5)","key":"10.1016\/j.critrevonc.2012.06.004_bib0085","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2007.06924.x","article-title":"Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas","volume":"140","author":"Salaverria","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"February (8)","key":"10.1016\/j.critrevonc.2012.06.004_bib0090","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1182\/blood-2011-01-328633","article-title":"Too much ara-C? Not enough daunorubicin?","volume":"117","author":"Feldman","year":"2011","journal-title":"Blood"},{"issue":"February (7)","key":"10.1016\/j.critrevonc.2012.06.004_bib0095","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1074\/jbc.M107653200","article-title":"Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR)","volume":"277","author":"Alonso","year":"2002","journal-title":"Journal of Biological Chemistry"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2012.06.004_bib0100","first-page":"49","article-title":"Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases","volume":"28","author":"Wang","year":"2009","journal-title":"Ai Zheng"},{"issue":"August (2)","key":"10.1016\/j.critrevonc.2012.06.004_bib0105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0002-9440(10)61724-5","article-title":"Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T\/null-cell lineage","volume":"159","author":"Rassidakis","year":"2001","journal-title":"American Journal of Pathology"},{"issue":"November (10)","key":"10.1016\/j.critrevonc.2012.06.004_bib0110","first-page":"3509","article-title":"Lymphomas expressing ALK fusion protein(s) other than NPM-ALK","volume":"94","author":"Falini","year":"1999","journal-title":"Blood"},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2012.06.004_bib0115","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1309\/R2Q9CCUVTLRYCF3H","article-title":"Anaplastic large cell lymphoma","volume":"127","author":"Medeiros","year":"2007","journal-title":"American Journal of Clinical Pathology"},{"issue":"October (39)","key":"10.1016\/j.critrevonc.2012.06.004_bib0120","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.3748\/wjg.v11.i39.6221","article-title":"Primary pancreatic anaplastic large cell lymphoma ALK negative: a case report","volume":"11","author":"Savopoulos","year":"2005","journal-title":"World Journal of Gastroenterology"},{"issue":"April (7)","key":"10.1016\/j.critrevonc.2012.06.004_bib0125","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/cncr.25654","article-title":"Breast implant-associated, ALK-negative T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity","volume":"117","author":"Lechner","year":"2011","journal-title":"Cancer"},{"issue":"September (9)","key":"10.1016\/j.critrevonc.2012.06.004_bib0130","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/MPH.0b013e31817e4a98","article-title":"Anaplastic large cell lymphoma in leukemic presentation: a case report and a review of the literature","volume":"30","author":"Takahashi","year":"2008","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2012.06.004_bib0135","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1440-1789.2008.00935.x","article-title":"Primary ALK-1-negative anaplastic large cell lymphoma of the brain: case report and review of the literature","volume":"29","author":"Kodama","year":"2009","journal-title":"Neuropathology"},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2012.06.004_bib0140","first-page":"1860","article-title":"Report of the Committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Research"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2012.06.004_bib0145","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"issue":"July (1)","key":"10.1016\/j.critrevonc.2012.06.004_bib0150","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"May (1)","key":"10.1016\/j.critrevonc.2012.06.004_bib0155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.1331","article-title":"ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects \u2013 a review","volume":"200","author":"ten Berge","year":"2003","journal-title":"Journal of Pathology"},{"issue":"September (5)","key":"10.1016\/j.critrevonc.2012.06.004_bib0160","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V86.5.1954.bloodjournal8651954","article-title":"Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM\/ALK: a distinct clinicopathologic entity","volume":"86","author":"Shiota","year":"1995","journal-title":"Blood"},{"issue":"April (7)","key":"10.1016\/j.critrevonc.2012.06.004_bib0165","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"May (2)","key":"10.1016\/j.critrevonc.2012.06.004_bib0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/157488707780599348","article-title":"New treatment concepts in diffuse large B-cell lymphomas (DLBL): chemotherapy and biological therapy","volume":"2","author":"Rodriguez","year":"2007","journal-title":"Review of Recent Clinical Trials"},{"issue":"Suppl. 4","key":"10.1016\/j.critrevonc.2012.06.004_bib0175","first-page":"iv125","article-title":"11-ICML (Lugano 2011)","volume":"22","author":"Sibon","year":"2011","journal-title":"Annals of Oncology"},{"issue":"November (9)","key":"10.1016\/j.critrevonc.2012.06.004_bib0180","first-page":"2993","article-title":"Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype","volume":"96","author":"Suzuki","year":"2000","journal-title":"Blood"},{"issue":"August (3)","key":"10.1016\/j.critrevonc.2012.06.004_bib0185","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2012.06.004_bib0190","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1996.14.3.955","article-title":"Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients","volume":"14","author":"Zinzani","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"November (18)","key":"10.1016\/j.critrevonc.2012.06.004_bib0195","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"October (7)","key":"10.1016\/j.critrevonc.2012.06.004_bib0200","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"September (9)","key":"10.1016\/j.critrevonc.2012.06.004_bib0205","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"July (14)","key":"10.1016\/j.critrevonc.2012.06.004_bib0210","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"February (4)","key":"10.1016\/j.critrevonc.2012.06.004_bib0215","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.V87.4.1243.bloodjournal8741243","article-title":"Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (\u00b1 radiotherapy) and autologous bone marrow transplantation","volume":"87","author":"Fanin","year":"1996","journal-title":"Blood"},{"issue":"September (1\u20132)","key":"10.1016\/j.critrevonc.2012.06.004_bib0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/10428199909145715","article-title":"The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center","volume":"35","author":"Fanin","year":"1999","journal-title":"Leukemia and Lymphoma"},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2012.06.004_bib0225","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"Nickelsen","year":"2009","journal-title":"Annals of Oncology"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2012.06.004_bib0230","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2012.06.004_bib0235","doi-asserted-by":"crossref","first-page":"320624","DOI":"10.1155\/2010\/320624","article-title":"Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas","volume":"2010","author":"Reimer","year":"2010","journal-title":"Advances in Hematology"},{"issue":"March (6)","key":"10.1016\/j.critrevonc.2012.06.004_bib0240","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2012.06.004_bib0245","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","article-title":"Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant","volume":"45","author":"Jagasia","year":"2004","journal-title":"Leukemia and Lymphoma"},{"issue":"April (7)","key":"10.1016\/j.critrevonc.2012.06.004_bib0250","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplantation"},{"issue":"October (1)","key":"10.1016\/j.critrevonc.2012.06.004_bib0255","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2141.1999.01666.x","article-title":"Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database Soci\u00e9t Fran\u00e7aise de Greffe de Moelle","volume":"107","author":"Dhedin","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"May (14)","key":"10.1016\/j.critrevonc.2012.06.004_bib0260","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"June (11)","key":"10.1016\/j.critrevonc.2012.06.004_bib0265","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"September (26)","key":"10.1016\/j.critrevonc.2012.06.004_bib0270","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II\u2013I\u2013II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O\u2019Connor","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"November (10)","key":"10.1016\/j.critrevonc.2012.06.004_bib0275","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1182\/blood-2003-02-0515","article-title":"The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma","volume":"102","author":"Borchmann","year":"2003","journal-title":"Blood"},{"issue":"July (19)","key":"10.1016\/j.critrevonc.2012.06.004_bib0280","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"July (2)","key":"10.1016\/j.critrevonc.2012.06.004_bib0285","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"15s","key":"10.1016\/j.critrevonc.2012.06.004_bib0290","article-title":"Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL)","volume":"27","author":"Bartlett","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl. 4","key":"10.1016\/j.critrevonc.2012.06.004_bib0295","article-title":"Durable remissions with SGN-35 (BRENTUXIMAB VEDOTIN): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)","volume":"22","author":"Shustov","year":"2011","journal-title":"Annals of Oncology"},{"issue":"June (23)","key":"10.1016\/j.critrevonc.2012.06.004_bib0300","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1182\/blood-2009-02-205476","article-title":"131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma","volume":"113","author":"Gopal","year":"2009","journal-title":"Blood"},{"issue":"December (24)","key":"10.1016\/j.critrevonc.2012.06.004_bib0305","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1158\/1078-0432.CCR-09-1421","article-title":"A phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma","volume":"15","author":"Dancey","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"November (32)","key":"10.1016\/j.critrevonc.2012.06.004_bib0310","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"December (13)","key":"10.1016\/j.critrevonc.2012.06.004_bib0315","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2004-09-3620","article-title":"Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas","volume":"106","author":"Mathas","year":"2005","journal-title":"Blood"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2012.06.004_bib0320","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2009.41","article-title":"The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis","volume":"23","author":"Zhang","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2012.06.004_bib0325","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8524","article-title":"Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases","volume":"27","author":"Dueck","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.06.004_bib0330","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281200131X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281200131X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T04:29:56Z","timestamp":1687580996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281200131X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S104084281200131X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2012.06.004","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}